NASDAQ:BDTX

Black Diamond Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy BDTX

*Your capital is at risk

$2.10

-0.0800 (-3.67%)

At Close: Jun 03, 2026

Black Diamond Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -79.68. In total, the insiders bought 5.6M and sold 12.01M BDTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-79.68
● Buy	5.6M shares
● Sell	12.01M shares
84% Buy Activity Moderate Positive Correlation
Buy Signal Low Confidence Jan 21, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -79.68. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 20, 2026 Buy	Common Stock A-Award	Behbahani Ali Director	Director	6 919 Value: $14.9K
Mar 20, 2026 Buy	Common Stock A-Award	Raman Prakash Director	Director	6 105 Value: $13.1K
Jan 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Velleca Mark A. President & CEO	CEO / President	600 000 Value: $1.54M
Jan 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Yurasov Sergey Chief Medical Officer	Officer	250 000 Value: $642.5K
Jan 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Buck Elizabeth Chief Scientific Officer	Officer	250 000 Value: $642.5K
Jan 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Hatzis-schoch Brent See Remarks	Officer	250 000 Value: $642.5K
Jan 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Jones Erika See Remarks	Officer	200 000 Value: $514.0K
Dec 12, 2025 Buy	Common Stock A-Award	Behbahani Ali Director	Director	5 208 Value: $14.4K
Dec 12, 2025 Buy	Common Stock A-Award	Raman Prakash Director	Director	4 665 Value: $12.9K
Sep 19, 2025 Buy	Common Stock A-Award	Behbahani Ali Director	Director	4 291 Value: $14.4K
Sep 19, 2025 Buy	Common Stock A-Award	Raman Prakash Director	Director	3 843 Value: $12.9K
Sep 19, 2025 Buy	Common Stock A-Award	Raman Prakash Director	Director	3 843 Value: $12.9K
Sep 19, 2025 Buy	Common Stock A-Award	Behbahani Ali Director	Director	4 291 Value: $14.4K
Jun 20, 2025 Buy	Common Stock A-Award	Behbahani Ali Director	Director	6 170 Value: $14.4K
Jun 20, 2025 Buy	Common Stock A-Award	Raman Prakash Director	Director	5 526 Value: $12.9K
Jun 20, 2025 Buy	Common Stock A-Award	Raman Prakash Director	Director	5 526 Value: $12.9K
Jun 20, 2025 Buy	Common Stock A-Award	Behbahani Ali Director	Director	6 170 Value: $14.4K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Behbahani Ali Director	Director	30 550 Value: $74.2K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Menzel Garry E Director	Director	30 550 Value: $74.2K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Raman Prakash Director	Director	30 550 Value: $74.2K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Campbell Shannon Director	Director	30 550 Value: $74.2K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Dhingra Kapil Director	Director	30 550 Value: $74.2K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Kulkarni Samarth Director	Director	30 550 Value: $74.2K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Kulkarni Samarth Director	Director	30 550 Value: $74.2K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Dhingra Kapil Director	Director	30 550 Value: $74.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BLACK DIAMOND THERAPEUTICS INC.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penet...

Read Full Profile Here